**Title**
COMPARISON OF PRESCRIPTION PROFILE OF ANTIRETROVIRALS DRUGS BETWEEN 2014 AND 2016 IN A TERTIARY CARE HOSPITAL CP-008

**Name**
E. Molina1, P. Nieto1, B. Franco1, S. Cañizares1, B. Tauste1, F. Sierra1.

**Address**
1Hospital Torrecárdenas, Hospital Pharmacy, Hermandad de los Donantes de Sangre s/n Almeria, Spain. PC 04009

**Background**
Antiretroviral therapy for treatment of human immunodeficiency virus type 1 (HIV-1) infection has improved steadily since the advent of combination therapy.

**Purpose**
To compare the prescription pattern of antiretroviral therapy between 2014 and 2016.

**Study Design**
Antiretroviral therapies used in the year 2014 were compared with those used in 2016 in patients affiliated with a tertiary care hospital of the Spanish Health System. Data were collected from medication consumption files of the institution.

**RESULTS**

604 patients were treated in 2014 using 71 different combinations whereas 618 patients were treated with 76 combinations during 2016. The male percentage was 73% both years. The total expenditure was 4.358.576€ in 2014 and 4.414.864€ in 2016 with an average cost per patient of 7.216€ and 7.144€ respectively. The ten most common combinations of 2014 were used to treat 73.51% of patients accounting for 69.31% of the total spending in antiretrovirals whereas the top ten combinations of 2016 accounted for 78.64% of patients and 74.51% of the total spending. Some of these combinations were in the top ten in 2014 but not in 2016. Similarly some new combinations reached the top ten in 2016. Taking into account altogether, 14 combinations were analyzed in order. The change in number and % of patients with these combinations between 2014 and 2016 were as follows: Emtricitabine/Tenofovir/Elavirenz [155 (25.66%), 91 (14.72%)], Emtricitabine/Tenofovir/Rilpivirine [64 (10.60%), 117 (18.93%)], Emtricitabine/Tenofovir/Lopinavir/Ritonavir [52 (8.61%), 6 (0.97%)], Emtricitabine/Tenofovir/Atazanavir/Ritonavir [48 (7.95%), 16 (2.59%)], Emtricitabine/Tenofovir/Darunavir/Ritonavir [28 (4.64%), 15 (2.43%)], Emtricitabine/Tenofovir/Nevirapine [25 (4.14%), 17 (2.75%)], Emtricitabine/Tenofovir/Raltegravir [22 (3.64%), 27 (4.37%)], Darunavir/Ritonavir [18 (2.98%), 10 (1.62%)], Lopinavir/Ritonavir [16 (2.65%), 6 (1.29%)], Abacavir/Lamivudine/Nevirapine [16 (2.65%), 8 (1.29%)], Emtricitabine/Tenofovir/Elvitegravir/Cobicistat [0 (0.00%), 95 (15.37%)], Abacavir/Lamivudine/Dolutegravir [0 (0.00%), 84 (13.59%)], Dolugravir/Rilpivirine [0 (0.00%), 14 (2.27%)], Emtricitabine/Tenofovir/Dolutegravir [0 (0.00%), 10 (1.62%)].

**CONCLUSION**

✓ Changes made from 2014 to 2016 have permitted a slight decrease in cost per patient. Emtricitabine/Tenofovir based therapies continue being the main antiretroviral backbone. It is observed a deep decrease in the use of protease inhibitors in favour of integrase inhibitor family, probably due to its better interaction pattern and metabolic profile.

✓ Acknowledgements
We thank Torrecardenas’ s hospital pharmacists for their support

There is not any conflict of interest at all.